PROBLEM TO BE SOLVED: To provide a method for determining responsiveness or a therapeutic effect of differentiation inducing agents to acute leukemia, or a therapeutic effect by leukemia therapeutic agents except the differentiation inducing agents early, accurately, and rapidly.SOLUTION: The invention provides a method for determining responsiveness or a therapeutic effect of differentiation inducing agents to acute leukemia, or a therapeutic effect by leukemia therapeutic agents except the differentiation inducing agents to acute leukemia, where PCAF in the biological sample derived from a subject or the expression level of the gene thereof is measured.COPYRIGHT: (C)2015,JPO&INPIT【課題】急性白血病に対する分化誘導薬の応答性若しくは治療効果、又は分化誘導薬以外の白血病治療薬による治療効果を早期、正確かつ迅速に判定する方法の提供。【解決手段】被検者由来の生体試料中のPCAF又はその遺伝子の発現量を測定することを特徴とする、急性白血病における分化誘導薬の応答性若しくは治療効果、又は急性白血病における分化誘導薬以外の白血病治療薬による治療効果の判定方法。【選択図】なし
